James Rolke
Amministratore Delegato presso REVELATION BIOSCIENCES, INC.
Patrimonio netto: 1 451 $ in data 30/04/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
George Tidmarsh | M | 64 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 12 anni |
Chester Zygmont | M | 44 |
Revelation Therapeutics LLC
Revelation Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Revelation Therapeutics LLC provides biotechnology services. The company is headquartered in Menlo Park, CA. | 9 anni |
Jennifer Carver | F | 70 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 10 anni |
Sandra Vedrick | F | - | 7 anni | |
Curt LaBelle | M | 53 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 3 anni |
Jess Roper | M | 59 |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | 4 anni |
Lakhmir Chawla | M | 53 | 7 anni | |
Luke Seikkula | M | 60 | 5 anni | |
Paula Rusu | F | - | 4 anni | |
Robin Marsden | M | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Nicholas Bacopoulos | M | 75 | - | |
Dennis Mulroy | M | 69 | 5 anni | |
Saiid Zarrabian | M | 71 | - | |
Deirdre Y. Gillespie | M | 67 | 6 anni | |
Robert A. Fildes | M | 85 | 21 anni | |
Gail A. Sloan | F | 61 | 16 anni | |
Daniel Gold | M | 70 |
Prospect Therapeutics, Inc.
Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | 1 anni |
Jeffrey Jensen | M | - | - | |
Robert H. Rosen | M | 68 | 8 anni | |
Craig Johnson | M | 62 | 9 anni | |
Laura Douglass | F | 59 | 9 anni | |
David Ramsay | M | 59 | 3 anni | |
Inge Bear | F | - | - | |
Carol Odle | F | - | 2 anni | |
Christopher Galloway | M | 53 | 2 anni | |
Darryl Wellinghoff | M | 55 | 1 anni | |
Joseph Ninosky | M | - | 1 anni | |
Clara Ezed | F | 52 | 3 anni | |
Wayne Coll | M | 60 |
Pluromed, Inc.
Pluromed, Inc. Medical SpecialtiesHealth Technology Pluromed, Inc. manufactures and markets disposable medical devices that are used to control bleeding during surgery. The company's trademark products include LeGoo Internal Vessel Occluder and BackStop. It was founded in 2003 and is located in Woburn, MA. | 2 anni |
Thomas J. Ouellette | M | - | 1 anni | |
Stewart M. Kroll | M | 65 | 5 anni | |
Bertrand C. Liang | M | 61 | 2 anni | |
Guy M. Gammon | M | - |
Prospect Therapeutics, Inc.
Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | - |
Kevin Tang | M | 57 | 8 anni | |
Michael E. Hanson | M | 74 |
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | 4 anni |
Brent Rutland | M | - | 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 36 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- James Rolke
- Contatti personali